Zentalis Pharmaceuticals Inc (ZNTL) Stock Price, Quote & News

Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 263 4333

Website: zentalis.com

Address:

10275 Science Center Dr., Suite 200, San Diego, United States

Sillyspuh May. 13 at 12:07 AM

$ZNTL Q1 2026 financial report: https://ir.zentalis.com/news--events/press-releases/press-releases-details/2026/Zentalis-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Clinical-Progress/default.aspx

0 · Reply

AbovetheGreenLine May. 8 at 1:51 PM

$ZNTL is Don't Take a Loss! https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/ALAFEXsBQr7Z

0 · Reply

Sillyspuh May. 5 at 5:49 PM

$ZNTL First dose given of phase 3 Aspenova confirmatory trial. A big accomplishment that should continue to derisk this stock. https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-announces-first-patient-dosed-aspenova

0 · Reply

Dark_Horse_Investments May. 4 at 11:18 PM

$ZNTL Taking a deeper dive into WEE1 gene inhibitor which blocks the G2/M checkpoint in certain ovarian cancers. From what I know/have learned, high grade serous ovarian cancer (HGSOC) significantly relies on WEE1 because they already live in a state of constant replication stress. Need to learn more of why this is. Yearly new ovarian cancer diagnosis in USA number 15k – 20k of which many will become platinum resistant. Current treatment is suboptimal, and none targets WEE1 (ie low ORR, ~4–13% & short DOR in PROC). I think there is something here… Any initial reactions about this pursuit? Stay longs & disciplined my friends!

0 · Reply

AbovetheGreenLine Apr. 27 at 7:10 PM

Swing Trade Buy on the Close for Zentalis Pharma. $ZNTL. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/z

0 · Reply

Snackdaddy Apr. 24 at 1:40 PM

$ZNTL wow. still dropping didnt see this going back to $2S but maybe

1 · Reply

Snackdaddy Apr. 22 at 6:03 PM

$ZNTL still getting beat up. can this actually retrace to $2S?

0 · Reply

Stef_Gee Apr. 22 at 11:29 AM

$ZNTL That was the original one ... 😉

1 · Reply

Stef_Gee Apr. 22 at 11:26 AM

$ZNTL 🫡

0 · Reply

Stef_Gee Apr. 22 at 11:22 AM

$ZNTL Again ... 😏

0 · Reply

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

May 5, 2026, 8:00 AM EDT - 7 days ago

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

May 1, 2026, 5:30 PM EDT - 11 days ago

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 21, 2026, 10:27 AM EDT - 21 days ago

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

2026-04-17T19:20:16.000Z - 25 days ago

Zentalis to present azenosertib preclinical data in TNBC at AACR meeting

Apr 17, 2026, 3:15 PM EDT - 25 days ago

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

2026-04-10T11:01:05.000Z - 4 weeks ago

Zentalis price target raised to $10 from $6 at Guggenheim

Apr 9, 2026, 8:00 AM EDT - 4 weeks ago

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Apr 1, 2026, 5:00 PM EDT - 5 weeks ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 26, 2026, 4:05 PM EDT - 6 weeks ago

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

Mar 17, 2026, 4:30 PM EDT - 2 months ago

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 9, 2026, 1:00 PM EDT - 2 months ago

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 10:30 AM EST - 2 months ago

Zentalis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 12:40 PM EST - 2 months ago

Zentalis Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 8:00 AM EST - 2 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Feb 11, 2026, 3:30 PM EST - 3 months ago

Zentalis Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 3, 2026, 4:05 PM EST - 3 months ago

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

2026-01-06T13:05:12.000Z - 4 months ago

Zentalis provides update, key milestones in 2025, expectations for 2026

Jan 6, 2026, 8:00 AM EST - 4 months ago

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Nov 12, 2025, 8:00 AM EST - 6 months ago

Zentalis Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 3:30 PM EST - 6 months ago

Zentalis Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-11T15:05:50.000Z - 6 months ago

Zentalis price target lowered to $4 from $8 at Morgan Stanley

Nov 10, 2025, 4:05 PM EST - 6 months ago

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Oct 13, 2025, 4:05 PM EDT - 7 months ago

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-09-24T19:40:20.000Z - 8 months ago

Zentalis board member Letai frontrunner to lead NCI, STAT reports

Sep 9, 2025, 7:00 AM EDT - 8 months ago

Zentalis Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 2:30 PM EDT - 8 months ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 10:15 AM EDT - 8 months ago

Zentalis Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

2025-08-26T20:10:19.000Z - 9 months ago

Zentalis CLO Andrea Paul to depart, James Bucher to succeed

Aug 26, 2025, 4:05 PM EDT - 9 months ago

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

2025-08-07T10:27:10.000Z - 9 months ago

Zentalis price target lowered to $5 from $6 at Wells Fargo

Aug 6, 2025, 4:05 PM EDT - 9 months ago

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Jun 4, 2025, 9:55 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: Jefferies Global Life Sciences Conference

May 27, 2025, 11:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 20, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

2025-05-15T13:07:58.000Z - 1 year ago

Zentalis price target lowered to $9 from $10 at Oppenheimer

May 14, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

2025-04-28T12:11:44.000Z - 1 year ago

Zentalis announces first patient dosed in DENALI Part 2 trial of azenosertib

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

2025-03-26T20:25:24.000Z - 1 year ago

Zentalis files $250M mixed securities shelf

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Mar 25, 2025, 4:40 PM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

2025-03-16T22:40:38.000Z - 1 year ago

Zentalis presents updated clinical data on azenosertib as SGO 2025

Mar 15, 2025, 11:25 AM EDT - 1 year ago

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Zentalis Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2025

Mar 3, 2025, 11:50 AM EST - 1 year ago

Zentalis Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

2025-01-30T13:21:32.000Z - 1 year ago

Zentalis price target lowered to $6 from $8 at Guggenheim

2025-01-30T12:42:35.000Z - 1 year ago

Zentalis price target lowered to $6 from $8 at Wells Fargo

2025-01-29T15:55:15.000Z - 1 year ago

Zentalis price target lowered to $10 from $20 at H.C. Wainwright

2025-01-29T15:20:22.000Z - 1 year ago

Zentalis price target lowered to $10 from $20 at Oppenheimer

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Transcript: Study Update

Jan 29, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Jan 28, 2025, 4:05 PM EST - 1 year ago

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Jan 9, 2025, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Dec 12, 2024, 7:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Nov 21, 2024, 1:14 PM EST - 1 year ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Oct 7, 2024, 2:03 PM EDT - 1 year ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Aug 19, 2024, 4:55 PM EDT - 1 year ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Sillyspuh May. 13 at 12:07 AM

0 · Reply

AbovetheGreenLine May. 8 at 1:51 PM

$ZNTL is Don't Take a Loss! https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/ALAFEXsBQr7Z

0 · Reply

Sillyspuh May. 5 at 5:49 PM

0 · Reply

Dark_Horse_Investments May. 4 at 11:18 PM

0 · Reply

AbovetheGreenLine Apr. 27 at 7:10 PM

Swing Trade Buy on the Close for Zentalis Pharma. $ZNTL. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/z

0 · Reply

Snackdaddy Apr. 24 at 1:40 PM

$ZNTL wow. still dropping didnt see this going back to $2S but maybe

1 · Reply

Snackdaddy Apr. 22 at 6:03 PM

$ZNTL still getting beat up. can this actually retrace to $2S?

0 · Reply

Stef_Gee Apr. 22 at 11:29 AM

$ZNTL That was the original one ... 😉

1 · Reply

Stef_Gee Apr. 22 at 11:26 AM

$ZNTL 🫡

0 · Reply

Stef_Gee Apr. 22 at 11:22 AM

$ZNTL Again ... 😏

0 · Reply

GSP Apr. 21 at 8:26 PM

$GLND $BIRD $XNDU $WSHP $ZNTL

0 · Reply

focafoca99 Apr. 21 at 4:51 PM

$ZNTL is taking ASCO data on azenosertib plus paclitaxel in platinum-resistant ovarian cancer as it keeps building the WEE1 inhibitor program.

0 · Reply

laurenlee Apr. 21 at 3:51 PM

$BBGI $CHOW $DKI $VTAK $ZNTL

1 · Reply

laurenlee Apr. 21 at 3:46 PM

$BBGI $CHOW $DKI $VTAK $ZNTL

0 · Reply

laurenlee Apr. 21 at 3:36 PM

$BBGI $CHOW $DKI $VTAK $ZNTL

0 · Reply

laurenlee Apr. 21 at 3:14 PM

$BBGI $CHOW $DKI $VTAK $ZNTL

0 · Reply

laurenlee Apr. 21 at 2:56 PM

$BBGI $CHOW $DKI $VTAK $ZNTL

0 · Reply

lucabrix Apr. 21 at 9:10 AM

$ZNTL Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is one of the must-buy small cap stocks to buy. On April 10, Jefferies raised its price target on Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) from $2.50 to $6.00 and left the Hold rating unchanged. This decision came after Zentalis said it had selected the optimal dose of its lead cancer drug azenosertib based on interim data from an ongoing clinical trial.

0 · Reply

GSP Apr. 21 at 2:23 AM

$WSHP $ZNTL $SIDU $MNTS

0 · Reply

Sillyspuh Apr. 20 at 3:20 PM

$ZNTL Nice entry point in the low 4's, I suspect

2 · Reply

zawojak Apr. 20 at 2:19 PM

$ZNTL WOOW POS of the week

0 · Reply

Stef_Gee Apr. 20 at 11:33 AM

$ZNTL

0 · Reply

Market Cap	294.71M
Revenue (ttm)	0.00
Net Income (ttm)	-137.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	435,600
Avg Vol	2,219,264
Day's Range	N/A - N/A
Shares Out	71.19M
Stochastic %K	68%
Beta	1.99
Analysts	Sell
Price Target	$6.25